Brief: Ardelyx Inc - Resubmission Of Xphozah New Drug Application Expected In Early Q2 2023

Ardelyx

02/03/2023 21:25

March 2 (Reuters) - Ardelyx Inc  ARDX.O :
    * ARDELYX REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * RESUBMISSION OF XPHOZAH NEW DRUG APPLICATION EXPECTED IN
EARLY
Q2 2023
    * QTRLY NET INCOME PER SHARE - BASIC AND DILUTED $0.06
    * Q4 EARNINGS PER SHARE VIEW $-0.00 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX2WRNS7 
Further company coverage:  ARDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))